Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1α

Gene Therapy

Volumn 10, Issue 25, 2003, Pages 2081-2089

  Sun, X ^a,b   Kanwar, J R ^a   Leung, E ^a   Vale, M ^a   Krissansen, G W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Angiogenesis inhibitors; Hypoxia inducible factor; Neoplasms; Von Hippel Lindau protein

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; HYPOXIA INDUCIBLE FACTOR 1; LIPOSOME; PROTEIN BCL 2; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENETIC CODE; GENETIC ENGINEERING; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REMISSION; THYMUS LYMPHOMA; TUMOR CELL; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; DNA; GENE EXPRESSION REGULATION; GENE THERAPY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INJECTIONS, INTRALESIONAL; LYMPHOMA; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDES, ANTISENSE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

ANIMALIA;

EID: 0344465865     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302118     Document Type: Article

References (43)

1. Kondo K, Kaelin WG. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001; 264: 117-125.
2. McKusick VA. Mendelian Inheritance in Man. Johns Hopkins University Press: Baltimore and London, 1992.
3. Krek W. VHL takes HIF's breath away. Nat Cell Biol 2000; 2: E1-E3.
4. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: tumor hypoxia as a therapy target. Cancer Metast Rev 1998; 17: 187-194.
5. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor-1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-4308.
6. 2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
7. Liu LX et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 2002; 291: 908-914.
8. Ohh M et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2: 423-427.
9. Yu F, White SB, Zhao Q, Lee FS. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001; 98: 9630-9635.
10. 2 sensing. Science 2001; 292: 464-468.
11. 2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
12. Lando D et al. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002; 295: 858-861.
13. Dann CE, Bruick RK, Deisenhofer J. Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc Natl Acad Sci USA 2002; 99: 15351-15356.
14. Jiang BH et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271: 17771-17778.
15. Ratcliffe PJ et al. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998; 201:1153-1162.
16. Semenza GL et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529-32537.
17. Dachs GU, Stratford IJ. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br J Cancer 1996; 74: S126-132.
18. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995; 1: 822-826.
19. Sun X et al. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy 2001; 8: 638-645.
20. Jiang B-H, Agani F, Passaniti A, Semenza GL. V-src induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-5335.
21. Feldser D et al. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 1999; 59: 3915-3918.
22. Kanwar JR et al. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1-mediated immunotherapy overcomes immune-resistance and leads to the eradication of large tumors. Cancer Res 2000; 61: 1948-1956.
23. Kanwar JR et al. Affect of survivin antagonists on the growth of established tumors and B7.1 immunogene therapy. J Natl Cancer Inst 2001; 93: 1541-1552.
24. Grimaite M, Werner-favre C, Kindler V, Zubler RH. Human naïve B cells cultured with EL-4 T cells mimic a germinal center-related B cell stage before generating plasma cells. Concordant changes in Bcl-2 protein and messenger RNA levels. Eur J Immunol 1997; 27: 199-205.
25. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-776.
26. Ponomarev ED, Tarasenko TN, Sapozhnikov AM. Splenic cytotoxic cells recognize surface HSP70 on culture-adapted EL-4 mouse lymphoma cells. Immunol Lett 2000; 74: 133-139.
27. Ohh M et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998; 1: 959-968.
28. Davidowitz EJ, Schoenfeld AR, Burk RD. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 2001; 21: 865-874.
29. Lieubeau-Teillet B et al. Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998; 58: 4957-4962.
30. Devarajan P et al. The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J Biol Chem 2001; 276: 40599-40605.
31. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 2001; 61: 1768-1775.
32. Koochekpour S et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999; 19: 5902-5912.
33. Pioli PA, Rigby WFC. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein A2 and regulates its expression. J Biol Chem 2001; 276: 40346-40352.
34. Los M et al. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1999; 59: 4440-4445.
35. Jiang Y et al. Gene expression profiling of a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 2003; 6: 453-462.
36. Wykoff CC et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene 2000; 19: 6297-6305.
37. Gnarra JR et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996; 93: 10589-10594.
38. Mack FA et al. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 2003; 3: 75-88.
39. Kanwar JR, Berg RW, Lehnert K, Krissansen GW. Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity. Gene Therapy 1999; 6: 1835-1844.
40. Sun X et al. Mouse B7-H3 induces antitumor immunity Gene Therapy 2003, in press.
41. Sun X et al. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of affects on vascular endothelial growth factor expression. Cancer Gene Ther 2001; 8: 719-727.
42. Kayar SR, Archer PG, Lechher AJ, Banchero N. Evaluation of the concentric-circles method for estimating capillary-tissue diffusion distances. Microvasc Res 1982; 24: 342-353.
43. Maxwell PH et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-8109.